Mesenchymal stem cell therapy

Phase 1Cell therapy

FFundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal

Mesenchymal stem cell therapy is one of 59 biologic programs targeting Bronchopulmonary Dysplasia. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Bronchopulmonary DysplasiaActive, not recruiting

COVID-19Active, not recruiting

Bronchopulmonary DysplasiaPhase 1

Active, not recruiting

COVID-19Preclinical

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Spikevax

Moderna

Preclinical

21 2

Bnt162b2

BioNTech

Preclinical

29 3

Proventil

Mylan Pharmaceuticals Inc

Preclinical

1 4

Aquasol E

NNational Eye Institute (NEI)

Preclinical

1 5

Glucocorticoid

AbbVie

Preclinical

1 6

Nadroparin

GSK

Preclinical

1 7

HB-Admscs

HHope Biosciences Research Foundation

Preclinical

4 8

Aprotinin

Bayer

Preclinical

1 9

Biological Collection

AAssistance Publique - Hôpitaux de Paris

Preclinical

1 10

Antihypertensive Agents

NNational Heart, Lung, and Blood Institute (NHLBI)

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

COVID-191 trial

Investigational Treatments for COVID-19 in Tertiary Care Hospital of Pakistan

Completed·UUNICEF·N/A·NCT04492501·600 enrolled

Bronchopulmonary Dysplasia1 trial

Mesenchymal Stem Cell Therapy for Bronchopulmonary Dysplasia in Preterm Babies

Completed·FFundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal·Phase 1·NCT02443961·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Mesenchymal stem cell therapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Mesenchymal stem cell therapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Mesenchymal stem cell therapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 1[1]
Company: FFundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal

Mesenchymal stem cell therapy

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

COVID-191 trial

Bronchopulmonary Dysplasia1 trial

References

Drug Info

Quick Facts

Related News